Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027

Pfizer remains deeply unloved on Wall Street, but it is slowly turning a corner.

Pfizer (PFE -0.51%) is facing challenges due to an upcoming patent cliff, with key drugs such as Eliquis expiring in 2028 and Vyndamax in 2031. However, the company has reported a significant 32% revenue growth in the third quarter of 2026 from its launched and acquired drugs, indicating progress in addressing the patent cliff issue.

Despite these achievements, investors have largely remained negative on Pfizer's stock, reflected in a high dividend yield of 6.1%, which is much higher than the S&P 500's 1.1% and the average pharma stock's 1.3%.

One of the reasons to consider buying Pfizer's stock is its robust balance sheet. As of the third quarter of 2026, Pfizer had $1.8 billion in cash and $12.4 billion in short-term investments, demonstrating a strong financial position that could help it navigate the patent expiration period. This financial strength, along with its stock's attractive valuation, makes it an intriguing investment opportunity.

Furthermore, Pfizer's commitment to maintaining and growing its dividend is evident in its strong cash dividend payout ratio of roughly 85%, despite earnings not fully covering the dividend. The company's leadership in the pharmaceutical industry, coupled with its focus on innovation and financial stability, makes it a compelling choice for investors looking for a reliable dividend stock.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at fool.com →

More in Finance & Markets

More from Friday 20 November →